13 January 2023

EU SolidAct publishes resuts on Baricitinib as a Treatment for Hospitalized COVID-19 Patients

The first drug tested on EU-SolidAct is baricitinib, a tablet approved for the treatment of rheumatoid arthritis, atopic dermatitis, and alopecia areata. Results of the Bari-SolidAct clinical trial, conducted in 14 European countries, have been published in Critical Care on January 10th 2023. While this trial was stopped early due to external evidence and is therefore underpowered to assess survival benefit, we observed a possible safety signal in vaccinated participants, who were older with more comorbidities.

https://pubmed.ncbi.nlm.nih.gov/36627655/

The EMA application for baricitinib was recently withdrawn.
https://www.ema.europa.eu/en/medicines/human/withdrawn-applications/olumiant